Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
PARP1 trapping at DNA lesion by pharmacological inhibitors has been exploited in several cancers exhibiting defects in DNA repair mechanisms. PARP1 hyperactivation is involved in therapeutic resistance in multiple cancers. The role of PARP1 in cervical cancer (CC) resistance and implication of PARP inhibitor is yet to be elucidated. Our data demonstrates significantly higher expression of PARP1 in primary cervical tumors and CC cell lines SiHa and ME180. Upon cisplatin treatment CC cells display significant overexpression of PARP1 and its hyperactivation. PARP inhibitor olaparib shows significant anti-proliferative effect on CC cells and drive loss of clonogenic survival and enhanced cell death in combination with cisplatin. PARP inhibited cells show delay in resolution of γH2A.X foci and prolonged late S and G2-M phase arrest resulting in apoptosis. Further, PARP inhibition disrupts the localization of base excision repair (BER) effector XRCC1 and non-homologous end joining (NHEJ) proteins Ku80 and XRCC4. Due to disrupted relocation of repair factors, cisplatin induced stalled replication forks collapse and convert into double strand breaks (DSBs). Interestingly, PARP inhibition also shows anti-migratory and anti-invasive properties in CC cells, increases anchorage independent cell death and induces anoikis. Collectively, our data demonstrates therapeutic potential of PARP inhibitor in cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 PARP1 inhibition delayed DNA repair and leads to prolonged cell cycle arrest at G2/M. (A) Both the cell lines SiHa and ME180 were treated with 10 µM cisplatin and/or olaparib for 24 hrs. After 24 hrs drug was removed (DR0) and fresh drug free media was added. Cells were cultured further and γH2A.X foci were observed very 24 hr till 10 days post drug removal (DR0 to DR10). Cells with >20 γH2A.X foci to 0 foci were counted in blind fashion and at least 200 cells per group in several different 60× objective fields were acquired. Quantitative plot displaying distribution of γH2A.X foci in three treatment groups in both the cell lines. [Time point DR3, frequency of cells with more than 20 foci per cell in SiHa; cisplatin vs. cisplatin + olaparib *p = 0.0467, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.0268, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0060 and frequency of cells with more than 20 foci per cell in ME180 at DR3; cisplatin vs. cisplatin + olaparib *p = 0.0390, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.041, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0024]. (B) Both the cell lines SiHa and ME180 were treated as indicated and cell were stained with FITC tagged anti γH2A.X & co-stained with PI and analysis was done using FACS for DNA damage in each cell cycle phases. Graph showing the percentage of cells with γH2A.X foci in SiHa and ME180 cell lines. PARP1 inhibition in cisplatin treated cells shows significant accumulation of DNA damage in late S and G2/M phase compared to G1. (C) Graph showing frequency of γH2A.X foci resolution in PARP1 silenced and control counterpart after cisplatin treatment. PARP1 silenced cells displayed significant delay in γH2A.X foci resolution after drug removal. (D) Similarly, PARP inhibition along with cisplatin treatment for 48 hrs shows significant & prolonged G2/M and late S phase arrest in both the cell lines after drug removal as in previous experiments.](https://figures.cochat.ai/paper-figures/eb3a147c582147ea983ae614c278bd55/olaparib-modulates-dna-repair-efficiency-sensitizes-cervical-cancer-cells-to-figure-7.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 1×
“1038/s41598-017-13232-3 of cell migration and invasion, cells were stained with CFSE [(5(6)-Carboxyfluorescein N-hydroxysuccinimidyl ester)] stain and migration and invasion assay was performed.”
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
d'AMOURS, D., DESNOYERS, S., d'SILVA, I., & POIRIER, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,815
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Cited by
PARP Inhibitors in Cancer Diagnosis and Therapy
Chan, C. Y., Tan, K. V., & Cornelissen, B. T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2766 · Cited by 114
“This trapping leads to DSB formation by stalling and collapsing replication forks (15) or accelerating fork elongation (3).”
BackgroundCurrent Treatment for Cervical Cancer: An Update
Sharma, S., Deep, A., & Sharma, A. K. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200224093301 · Cited by 115
Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4
Mo, L., Song, M. S., Huang, Q.-H., Guan, H., Liu, X., Xie, D.-F., Huang, B., Huang, R., & Zhou, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0192-9 · Cited by 102
Penninckx, S., Pariset, E., Cekanaviciute, E., & Costes, S. V. (2021) · NAR Cancer · doi:10.1093/narcan/zcab046 · Cited by 111
Schoonen, P. M., Kok, Y. P., Wierenga, E., Bakker, B., Foijer, F., Spierings, D. C. J., & van Vugt, M. A. T. M. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12573 · Cited by 81
PARP inhibitors in ovarian cancer: An overview of the practice‐changing trials
Foo, T., George, A. J., & Banerjee, S. N. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22935 · Cited by 78
“Preclinical trials have suggested that PARPi may sensitize CC cells to cisplatin.(82,83,84) A phase 1 (NCT01281852) study reported that the combination of veliparib with paclitaxel and cisplatin in persistent or recurrent cervical carcinoma is feasible.”
BackgroundInsights into therapy resistance in cervical cancer
George, I. A., Chauhan, R., Dhawale, R. E., Iyer, R., Limaye, S. A., Sankaranarayanan, R., Venkataramanan, R., & Kumar, P. (2022) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2022.100074 · Cited by 57
Hegedűs, C., Boros, G., Fidrus, E., Kis, G. N., Antal, M., Juhász, T., Janka, E. A., Jankó, L., Paragh, G., Emri, G., et al. (2019) · Cancers · doi:10.3390/cancers12010005 · Cited by 55
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Yusoh, N. A., Ahmad, H., & Gill, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000391 · Cited by 57
Cisplatin in the era of PARP inhibitors and immunotherapy
Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 54
The developmental origin of cancers defines basic principles of cisplatin resistance
Skowron, M. A., Oing, C., Bremmer, F., Ströbel, P., Murray, M. J., Coleman, N., Amatruda, J. F., Honecker, F. U., Bokemeyer, C., Albers, P., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.037 · Cited by 50
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
Wu, M., Liu, J., Hu, C., Li, D., Yang, J., Wu, Z., Yang, L., Chen, Y., Fu, S., & Wu, J. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s181546 · Cited by 43
“Poly (ADP-ribose) polymerase (PARP) is a DNA damage-sensing protein, which is the key enzyme in the repair of DSBs.6 PARP inhibitor (PARPi) has been known as sensitizers, which enhanced the therapeutic effect of chemotherapy or RT.5 PARPi arrested PARP release from damaged DNA.7 As a result, DNA repair proteins were u…”
BackgroundPARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib
Bianchi, A., Lopez, S., Altwerger, G. H., Bellone, S., Bonazzoli, E., Zammataro, L. A., Manzano, A., Manara, P., Perrone, E., Zeybek, B., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.08.010 · Cited by 46
“, HRD), as well as their level of PARP1 expression [20, 32], and the potential role played by PARylation.”
BackgroundYusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
Zhang, C., Sheng, Y., Sun, X., & Wang, Y. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10113-2 · Cited by 39
“Preclinical research has demonstrated that PARPis boost apoptotic response and make CC cells more sensitive to cisplatin [243–245].”
BackgroundAlemasova, E. E., Naumenko, K. N., Kurgina, T. A., Anarbaev, R. O., & Lavrik, O. I. (2018) · Oncotarget · doi:10.18632/oncotarget.25158 · Cited by 39
“com PARP1 upregulation and its increased activation accompanied by elevated levels of PAR-containing proteins were actually observed in cisplatin-resistant cell clones [71, 75].”
BackgroundPARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
Mann, M., Kumar, S., Sharma, A. K., Chauhan, S. S., Bhatla, N., Kumar, S., Bakhshi, S., Gupta, R., & Kumar, L. (2019) · Oncotarget · doi:10.18632/oncotarget.27008 · Cited by 35
“The role of PARP-1 inhibitors in decreasing DNA damage repair and promoting synthetic lethality in BRCA-mutated cancer is already well known [37].”
Cervical cancer: a tale from HPV infection to PARP inhibitors
Mann, M., Singh, V. P., & Kumar, L. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.09.014 · Cited by 34
“X foci.(76) Similarly, rucaparib also has a significant anti-proliferative effect; it causes G2/M arrest, reduces cyclin D1 and CDK4 expression, and suppresses cancer growth in vivo and in vitro.”
BackgroundMolla, S., Hembram, K. C., Chatterjee, S., Nayak, D., Sethy, C., Pradhan, R., & Kundu, C. N. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00768-0 · Cited by 34
Nguyen, T. V., Winterman, S., Playe, M., Benbara, A., Zelek, L. H., Pamoukdjian, F., & Bousquet, G. (2021) · Cancers · doi:10.2139/ssrn.3844912 · Cited by 34
NAD Modulates DNA Methylation and Cell Differentiation
Ummarino, S., Hausman, C., Gaggi, G., Rinaldi, L., Bassal, M. A., Zhang, Y., Seelam, A. J., Kobayashi, I. S., Borchiellini, M., Ebralidze, A. K., et al. (2021) · Cells · doi:10.3390/cells10112986 · Cited by 31
“In order to further validate the hypothesis of a PARP1-dependent demethylating mechanism, a pharmacological inhibition of PARP1 with Olaparib [38,39] was performed in addition to the NAD treatment.”
MethodBerning, L., Scharf, L., Aplak, E., Stucki, D., von Montfort, C., Reichert, A. S., Stahl, W., & Brenneisen, P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222267 · Cited by 30
“leukemia [81], primary cervical tumors and cervical cancer cell lines [82] which was described to be associated with tumor progression and metastasis as well as a poor prognosis [83], whereby the mechanisms leading to that high PARP level have not been completely understood until now.”
BackgroundAbraham, J., O’Connor, L. O., Grybowicz, L., Pinilla, K., Dayimu, A., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59151-0 · Cited by 29
Tian, S., Lou, L., Tian, M., Lu, G., Tian, J., & Chen, X. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01644-5 · Cited by 30
“Previous study showed that PARP1 hyperactivation leads to therapeutic resistance, and the therapeutic potential of PARP inhibition in combination with cisplatin has shown profound anti-cancer effect in cervical cancer [18].”
BackgroundRecent progress of the tumor microenvironmental metabolism in cervical cancer radioresistance
Zhou, J., Lei, N., Tian, W., Guo, R., Chen, M., Qiu, L., Wu, F., Li, Y., & Chang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.999643 · Cited by 34
“Orapanib, a PARP inhibitor, destroyed the localization of base excision repair effector XRCC1 and NHEJ proteins Ku80 and XRCC4, enhanced the sensitivity of cervical cancer cells to cisplatin, demonstrating the potential of PARP inhibitors in the treatment of cervical cancer (77).”
BackgroundPARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Lightfoot, M. D. S., Montemorano, L., & Bixel, K. L. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0873-4 · Cited by 27
Targeting cervical cancer: Is there a role for poly (ADP‐ribose) polymerase inhibition?
Tomao, F., Santangelo, G., Musacchio, L., Donato, V. D., Fischetti, M., Giancotti, A., Perniola, G., Petrella, M. C., Monti, M., Palaia, I., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29440 · Cited by 26
Sriramkumar, S., Matthews, T. D., Ghobashi, A. H., Miller, S. A., VanderVere-Carozza, P. S., Pawelczak, K. S., Nephew, K. P., Turchi, J. J., & O’Hagan, H. M. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0396 · Cited by 27
“Cisplatin treatment increased RPA32 punctate foci which colocalized with the damage marker γH2AX compared to untreated cells (Figure 4B, Supplementary Figure S5A) as has been demonstrated by others (40).”
Yusoh, N. A., Leong, S. W., Chia, S. L., Harun, S. N., Rahman, M. B. A., Vallis, K. A., Gill, M. R., & Ahmad, H. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.9b00843 · Cited by 24
Quiñonero, F., Mesas, C., Muñoz‐Gámez, J. A., Jiménez‐Luna, C., Perazzoli, G., Prados, J. C., Melguizo, C., & Ortíz, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113669 · Cited by 25
Yan, Y., Dai, T., Guo, M., Zhao, X., Chen, C., Zhou, Y., Qin, M., Xu, L., & Zhao, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132686 · Cited by 28
Chowdhury, P. R., Dey, P., De, D., & Ghosh, U. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1711461 · Cited by 23
“It is reported that olaparib treatment alone reduces metastatic potential of cells (Prasad et al. 2017).”
BackgroundRaspaglio, G., Buttarelli, M., Filippetti, F., Battaglia, A., Buzzonetti, A., Scambia, G., & Gallo, D. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04229-y · Cited by 25
Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer
Wen, X., Liu, S., Sheng, J., & Cui, M. (2020) · PeerJ · doi:10.7717/peerj.9234 · Cited by 21
“Indeed, the PARP inhibitor olaparib has been shown to enhance the sensitivity of CC cells to CDDP (Prasad et al., 2017), substantiating the potential for miRNAs to provide new therapeutic targets.”
BackgroundLi, R., Zhao, W., Chen, J., & Xiong, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106354 · Cited by 20
Targeting DNA Double-Strand Break (DSB) Repair to Counteract Tumor Radio-resistance
Zhao, Y., & Chen, S. (2019) · Current Drug Targets · doi:10.2174/1389450120666190222181857 · Cited by 20
Herath, N. I., Berthault, N., Thierry, S., Jdey, W., Lienafa, M.-C., Bono, F., Noguiez, P., Sun, J., & Dutreix, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01097 · Cited by 19
“Whereas, olaparib inhibits the formation of foci of XRCC1 and PARP1 (14), it has no”
BackgroundYusoh, N. A., Chia, S. L., Saad, N., Ahmad, H., & Gill, M. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-28454-x · Cited by 18
Gasimli, K., Raab, M., Rad, M. T., Kurunci‐Csacsko, E., Becker, S., Strebhardt, K., & Sanhaji, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810892 · Cited by 18
“Mechanistically, blocking PARP enzymatic activity upon DNA damage triggers the conversion of ssDNA breaks to lethal DSBs [69].”
BackgroundInfluentialWang, J., Xiu, J., Battaglin, F., Arai, H., Soni, S., Zhang, W., Goldberg, R. M., Philip, P. A., Seeber, A., Hwang, J. J., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00694-8 · Cited by 17
Juncheng, P., Joseph, A., Lafarge, A., Martins, I., Obrist, F., Pol, J. G., Saavedra, E., Li, S., Sauvat, A., Cerrato, G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004280 · Cited by 16
Chan, C. Y., Hopkins, S. L., Guibbal, F., Pacelli, A., Torres, J. B., Mosley, M. J., Lau, D., Isenegger, P. G., Chen, Z., Wilson, T. C., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00940-9 · Cited by 15
“Several studies have reported that PARP1-DNA trapping induces conversion of SSBs into DSBs after replication, thereby enhancing DSB levels, although these studies were performed over time scales of several days [24, 25].”
BackgroundQuiñonero, F., Parra‐Torrejón, B., Ramírez‐Rodríguez, G. B., Garcés, V., Delgado‐López, J. M., Jiménez‐Luna, C., Perazzoli, G., Melguizo, C., Prados, J. C., & Ortíz, R. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s415631 · Cited by 14
Macias, R. M., Koual, M., Crespel, C., Belda, M. A. L. F., Blons, H., Nguyen-Xuan, H.-T., Garinet, S., Perkins, G., Balay, V., Durdux, C., et al. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02767-9 · Cited by 14
“showed that CC cells exhibit high amounts of PARP1 and that expression level is significantly higher in stages IIB and IIIB as compared with IIA (FIGO 2009) [16].”
PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation
IJff, M., van Bochove, G. G. W., Whitton, D., Winiarczyk, R., Honhoff, C., Rodermond, H. M., Crezee, J., Stalpers, L. J. A., Franken, N. A. P., & Oei, A. L. (2021) · Cancers · doi:10.3390/cancers13092092 · Cited by 13
“PARP1-i alone or in combination with platinum-based therapeutics, such as cisplatin, has shown to have antitumor activity in cancers with DNA repair defects [33].”
BackgroundModi, A., Singh, M., Gutti, G., Shanker, O. R., Singh, V. K., Singh, S., Singh, S. K., Pradhan, S., & Narayan, G. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00848-7 · Cited by 15
“PARP-1 is a chromatin-bound nuclear enzyme which modifies various nuclear proteins by poly(ADP-ribosyl)ation and is also involved in regulation of the molecular events involved in the recovery of cell from DNA damage [38].”
BackgroundSelf-citationBošnjak, M., Jesenko, T., Markelc, B., Janžič, L., Čemažar, M., & Serša, G. (2021) · Bioelectrochemistry · doi:10.1016/j.bioelechem.2021.107832 · Cited by 12
Honc, O., & Novotný, J. (2023) · Cancers · doi:10.3390/cancers15143567 · Cited by 10
Cao, P., Wang, Y., Lv, Y., Jiang, N., Zhong, L., Ma, X., Xiao, X., Ding, D., Gu, J., Lin, L., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7313 · Cited by 9
Zhang, S., Li, E., Liu, Z., Shang, H., Chen, Y., & Jing, H. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103731 · Cited by 8
Mórocz, M., Qorri, E., Pekker, E., Tick, G., & Haracska, L. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.12.001 · Cited by 9
Enzymatic Processing of DNA–Protein Crosslinks
Essawy, M. M., & Campbell, C. (2024) · Genes · doi:10.3390/genes15010085 · Cited by 9
Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
Gross, M., & Spencer, R. J. (2022) · Case Reports in Obstetrics and Gynecology · doi:10.1155/2022/6579715 · Cited by 7
“Another study demonstrated in vitro efficacy of olaparib when used as a single-agent as well as when used as a sensitizing agent with concurrent cisplatin administration [14].”
BackgroundEnhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib
Zhang, T., Li, X., Wu, L., Su, Y., Yang, J., Zhu, X., & Li, G. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1364975 · Cited by 8
Pharmacotherapy for cervical cancer: current standard of care and new perspectives
Ketch, P. W., Zaharias, R. S., & Leath, C. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2395379 · Cited by 6
Poly(ADP-ribose) polymerase1 (PARP1) and PARP inhibitors: New frontiers in cervical cancer
Rajawat, J., & Banerjee, M. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150943 · Cited by 9
Legartová, S., Kovaříková, A. S., Suchánková, J., Polášek-Sedláčková, H., & Bártová, E. (2022) · RNA Biology · doi:10.1080/15476286.2022.2139109 · Cited by 7
HIF1A-mediated pathways promote euploid cell survival in chromosomally mosaic embryos
Sánchez-Vásquez, E., Bronner-Fraser, M. E., & Zernicka‐Goetz, M. (2025) · eLife · doi:10.1101/2023.09.04.556218 · Cited by 5
Anti-cancer agent Olaparib ameliorates doxorubicin-induced cardiotoxicity in vitro and in vivo
Chen, D., Croft, A. J., Haw, T. J., Kelly, C., Balachandran, L., Sverdlov, A. L., & Ngo, D. T. M. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.07.015 · Cited by 4
Yusoh, N. A., Su, L., Chia, S. L., Tian, X., Ahmad, H., & Gill, M. R. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70093 · Cited by 4
“This has seen numerous DNA-damaging agents achieve synergy with PARPi, including platinum drugs [12,13], doxorubicin [14], and gemcitabine [15], while targeting alternative DNA repair pathways has also achieved success in this capacity [16,17].”
HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer
Citro, S., Ghiani, L., Doni, M., Miccolo, C., Tagliabue, M., Ansarin, M., & Chiocca, S. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107307 · Cited by 4
Parida, B. P., Radhakrishnan, M., Goyal, V., Sharma, A., Zarekar, R., Ansari, M. A., Singh, J., Singh, S., & Narayan, G. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100273 · Cited by 4
Self-citationKhamto, N., Utama, K., Chawapun, P., Siriphong, S., Tateing, S., Duangdesh, S., Sangthong, P., Chomsri, N.-O., & Meepowpan, P. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117705 · Cited by 3
Lourenço, R., Lança, M. B., Gil, O. M., Cardoso, J., Lourenço, T., Pereira‐Leal, J. B., Rodrigues, A. S., Rueff, J., & Silva, S. (2023) · Molecular Medicine Reports · doi:10.3892/mmr.2023.13023 · Cited by 3
IJff, M., Mei, X., Scutigliani, E. M., Rodermond, H. M., van Bochove, G. G. W., Krawczyk, P. M., Franken, N. A. P., Stalpers, L. J. A., Crezee, J., & Oei, A. L. (2025) · International Journal of Hyperthermia · doi:10.1080/02656736.2025.2450514 · Cited by 3
“Previous research by Prasad et al. has also shown that PARP1 -i combined with cDDP leads to induced apoptosis in cervical cancer cells and has anti-metastatic effects on cervical cancer tumors [30].”
Ogasawara, A., Suzuki, S., Oda, K., Yunokawa, M., Yonemori, K., Mori, M., Kurosaki, A., Mori, M., Kitano, S., Shintani, D., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.04.007 · Cited by 2
Dutta, P., Pal, D., Sultana, F., Mandal, R., Roy, A. K., & Panda, C. K. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01378-7 · Cited by 2
“Some previous studies have already shown that induction of the FA-BRCA pathway was associated with non-responsiveness to therapy in carcinoma patients [25, 26].”
Mechanisms of chemotherapy resistance in cervical cancer
Marima, R. M., Mosoane, B., Mtshali, N. Z., Basera, A., Kgatle, M., Grech, G., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28985-9.00012-4 · Cited by 2
Suppression of CTC1 inhibits hepatocellular carcinoma cell growth and enhances RHPS4 cytotoxicity
Kıpçak, A., Sezan, S., Karpat, O., Kaya-Aksoy, E., Baylan, S. M., Sarıyar, E., Yandım, C., & Karagonlar, Z. F. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09756-3 · Cited by 2
“One key observation in most of such studies is that the efficacy of the first-line regimen is dramatically enhanced upon combination with DNA repair targeting [ 47 , 48 ].”
Cross-Talk Between DNA Damage and Autophagy and Its Implication in Cancer Therapy
Bellare, G. P., Gupta, P., Chakraborty, S., Tyagi, M., & Patro, B. S. (2020) · Springer eBooks · doi:10.1007/978-981-15-6930-2_3 · Cited by 2
Kam, C. M. T., Tauber, A. L., Zunk, M., McDermott, C., Levonis, S. M., & Schweiker, S. S. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2437972 · Cited by 1
Anticancer potential of Curcuma caesia: induction of DNA damage and apoptosis in cervical cancer
Radhakrishnan, M. P., Parida, B. P., Shekhar, H., Singh, P., Ansari, M. A., Singh, J., Singh, S., & Narayan, G. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-026-05351-0 · Cited by 1
“Optical density values were obtained at 570 nm using BIO-RAD iMark microplate reader [12].”
Self-citationHIF1A-mediated pathways promote euploid cell survival in chromosomally mosaic embryosPreprint
Sánchez-Vásquez, E., Bronner-Fraser, M. E., & Zernicka‐Goetz, M. (2025) · eLife · doi:10.7554/elife.101912 · Cited by 1
Additive Cox proportional hazards models for next-generation sequencingdata
Alshanbari, H. M. (2017) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Examining Novel Combination Therapies for Pancreatic Cancer
Kerns, M. C. (2019) · Digital WPI
Shao, D., Zhou, H., Yu, H., Luo, P., Cheng, Z., & Zhu, X. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.065
RetractedDeoxyribonucleic Acid Damage Response Defects
Yin, M., Pomerantz, L. D., Vaca, R. A., Grivas, P. D., & Joshi, M. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.006
Dutta, P., Pal, D., Sultana, F., Mandal, R., Roy, A. K., & Panda, C. K. (2022) · Research Square · doi:10.21203/rs.3.rs-1944207/v1
Tian, S., Lou, L., Tian, M., Lu, G., Tian, J., & Chen, X. (2020) · Figshare · doi:10.6084/m9.figshare.12720107
Tian, S., Lou, L., Tian, M., Lu, G., Tian, J., & Chen, X. (2020) · Figshare · doi:10.6084/m9.figshare.12720104
Chan, C. Y., Hopkins, S. L., Guibbal, F., Pacelli, A., Torres, J. B., Mosley, M. J., Lau, D., Isenegger, P. G., Chen, Z., Wilson, T. C., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303674
Quiñonero Muñoz, F. J. (2023) · Institutional Repository of the University of Granada (University of Granada) · Cited by 1
Kim, B., Nguyen, T. O. O., Nguyen, B. L., Le, N. D., Kim, J. O., & Kim, J. (2025) · Macromolecular Research · doi:10.1007/s13233-025-00483-7
Molecular Insights and Therapeutic Innovations in Cervical Cancer: Emerging Drug Targets
Debnath, A., Singh, R. K., Mazumder, R., Dua, A., Tyagi, P. K., & Singh, A. K. (2026) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/1452252
Parida, B. P., Thapliyal, S., Mishra, A., Gopichand, B., Melge, A. R., Melethadathil, N., Radhakrishnan, M. P., Singh, S., & Narayan, G. (2026) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2026.100381
Self-citationTherapy resistance-related ncRNAs in cervical cancer: biomarkers and therapeutic targets
Liu, L., Zhang, L., & Ma, Z. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00660-8
“In addition, inhibition of PARP-mediated single-strand break repair can sensitize CC cells to platinum agents, highlighting the role of compensatory repair pathways in resistance [ 17, 60, 61].”
Metadata
- Authors
- Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G.
- Affiliations
- Banaras Hindu University (IN)
- Institute of Medical Sciences (IN)
- Corresponding author
- Narayan, Gopeshwar
- ORCID
- Venue
- Scientific Reports
- Published
- 2017-10-09
- Volume
- 7
- Issue
- 1
- Pages
- 12876-12876
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5634505
- OpenAlex
- W2762572114
- Cited by
- 84
- References
- 64
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 11 · 2023: 8 · 2022: 14 · 2021: 9 · 2020: 14 · 2019: 10 · 2018: 3 · 2017: 1
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- olaparib, PARP1, cervical cancer, cisplatin, PARP inhibitors, DNA repair, base excision repair, non-homologous end joining, replication fork collapse, DNA double-strand breaks, apoptosis, cell migration and invasion, anoikis, treatment resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Uterine Cervical Neoplasms, Cisplatin, DNA Repair, DNA Replication, Female, Humans, Neoplasm Metastasis, Nuclear Proteins, Phthalazines, Piperazines, Apoptosis, Gene Silencing, Cell Line, Tumor, DNA Breaks, Double-Stranded, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.